Product Description
| Cat Number | HB863016 |
|---|---|
| Category | Biosimilar |
| Pack Size | 100 ug |
| Description | Bemarituzumab(bema),afirst-in-classhumanizedIgG1monoclonalantibody,selectivelybindsto2bIsoformofthefibroblastgrowthfactorreceptor(FGFR2b).Bemarituzumab(FPA144)isafirst-in-classhumanizedimmunoglobulinG1monoclonalantibodyspecifictothesplice-variantFGFR2bthatinhibitsbindingoftheligandsFGF7,FGF10,andFGF22.Specifically,bemarituzumabdoesnotinhibitbindingofFGF23,theligandresponsibleforphosphateandvitaminDmetabolism,therebypotentiallyavoidingtheriskofhyperphosphatemiaassociatedwithpan-FGFRtyrosinekinaseinhibitors.BemarituzumabisalsoglycoengineeredforincreasedaffinityforthehumanFcgammaRIIIAreceptorexpressedonnaturalkillercells,enablingenhancedantibody-dependentcellmediatedcytotoxicity. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | K-sam,KSAM,CD332,Keratinocytegrowthfactorreceptor,Fibroblastgrowthfactorreceptor2,FGFR-2,FGFR2,KGFR,BEK |
| Clonality | Monoclonal |
| Synonyms | FPA144,FPA-144,FPA114-A,CAS:1952272-74-0 |
| Host | Humanized |
| Concentration | 1mg/ml |
| Isotype | IgG1-kappa |
| Form | Liquid |
| Purity | >95% as determined by SDS-PAGE. |
| Specie Reactivity | Human |
| Storage | 0.01M PBS, pH7.4. |
| Note | The product is for research use only |
Share Item: